| | 54573-75-0 Basic information More.. |
| Product Name: | Doxercalciferol | | Synonyms: | 1-alpha-hydroxyergocalciferol;1alpha-hydroxyergocalciferol;1-alpha-hydroxyvitamind2;1-hydroxyergocalciferol;1ALPHA-OH-D2;7,10(19),22-tetraene-1,3-diol,(1-alpha,3-beta,5z,7e,22e)-10-secoergosta-5;VITAMIN D2, 1ALPHA-HYDROXY-;Vitamin D2, 1a-Hydroxy- | | CAS: | 54573-75-0 | | MF: | C28H44O2 | | MW: | 412.65 | | EINECS: | | | Mol File: | 54573-75-0.mol |  |
Use
Doxercalciferol is a synthetic vitamin D2 analog introduced in the US as
Hectorol for the treatment of secondary hyperparathyroidism (SHPT) in patients
with end-stage renal failure. It is actually 1-alpha-hydroxyvitamin D2 (one-alpha-
D2) and can be synthesized by direct hydroxylation of vitamin D2 tosylate or in
5 steps from ergosterol. Doxercalciferol itself is inactive until metabolized by the
liver into active 1,24-dihydroxyvitamin D2, showing a pharmacokinetic profile
similar to calcitriol. During placebo-controlled clinical trials, patients with
moderate to severe SHPT were treated with 1-alpha-D2 (10 μg doses) for 16 to
24 weeks; in 9 patients out of 10, blood levels of parathyroid hormone were
considerably reduced, so maintaining a good control of the parathyroid
hyperplasia. Moreover, only a moderate tendency to raise calcium and
phosphate was observed. Doxercalciferol is orally-active and less toxic than
other vitamin D analogs like alfacalcidol; it shows differentially controlled effects
and has an improved safety profile compared to calcitriol.Doxercalciferol is a synthetic vitamin D2 analog introduced in the US as
Hectorol for the treatment of secondary hyperparathyroidism (SHPT) in patients
with end-stage renal failure. It is actually 1-alpha-hydroxyvitamin D2 (one-alpha-
D2) and can be synthesized by direct hydroxylation of vitamin D2 tosylate or in
5 steps from ergosterol. Doxercalciferol itself is inactive until metabolized by the
liver into active 1,24-dihydroxyvitamin D2, showing a pharmacokinetic profile
similar to calcitriol. During placebo-controlled clinical trials, patients with
moderate to severe SHPT were treated with 1-alpha-D2 (10 μg doses) for 16 to
24 weeks; in 9 patients out of 10, blood levels of parathyroid hormone were
considerably reduced, so maintaining a good control of the parathyroid
hyperplasia. Moreover, only a moderate tendency to raise calcium and
phosphate was observed. Doxercalciferol is orally-active and less toxic than
other vitamin D analogs like alfacalcidol; it shows differentially controlled effects
and has an improved safety profile compared to calcitriol.Doxercalciferol is a synthetic vitamin D2 analog introduced in the US as
Hectorol for the treatment of secondary hyperparathyroidism (SHPT) in patients
with end-stage renal failure. It is actually 1-alpha-hydroxyvitamin D2 (one-alpha-
D2) and can be synthesized by direct hydroxylation of vitamin D2 tosylate or in
5 steps from ergosterol. Doxercalciferol itself is inactive until metabolized by the
liver into active 1,24-dihydroxyvitamin D2, showing a pharmacokinetic profile
similar to calcitriol. During placebo-controlled clinical trials, patients with
moderate to severe SHPT were treated with 1-alpha-D2 (10 μg doses) for 16 to
24 weeks; in 9 patients out of 10, blood levels of parathyroid hormone were
considerably reduced, so maintaining a good control of the parathyroid
hyperplasia. Moreover, only a moderate tendency to raise calcium and
phosphate was observed. Doxercalciferol is orally-active and less toxic than
other vitamin D analogs like alfacalcidol; it shows differentially controlled effects
and has an improved safety profile compared to calcitriol.Doxercalciferol isCrystalline Solid
- Doxercalciferol
-
- US $48.00-173.00 / mg
- 2024-10-28
- CAS:54573-75-0
- Min. Order:
- Purity: 99.69%
- Supply Ability: 10g
- Doxercalciferol
-
- US $15.00-10.00 / KG
- 2021-07-13
- CAS:54573-75-0
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Supply Ability: Monthly supply of 1 ton
|
|
54573-75-0
Recommend Suppliers |
|